Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

This study tests whether combining an immunotherapy drug called cadonilimab with radiation therapy can effectively treat women with locally advanced cervical cancer who cannot tolerate standard chemotherapy alongside radiation. **You may be eligible if...** - You are a woman aged 18 or older - You have locally advanced cervical cancer confirmed by biopsy (squamous cell, adenocarcinoma, or adenosquamous type) - Your cancer is at FIGO stage IB3, IIA2, IIB, or up to IVA (advanced but not yet spread to distant organs) - You are unable to tolerate standard chemotherapy - You have at least one measurable tumor on imaging - You are in reasonable health (ECOG 0–2) with a life expectancy of at least 12 weeks **You may NOT be eligible if...** - Your cervical cancer has spread to distant organs (stage IVB) - You have already had a total hysterectomy - Your cancer is a rare type (e.g., neuroendocrine or small cell) - You have received prior systemic treatment for cervical cancer - You are pregnant Talk to your doctor to see if this trial is right for you.